Transgene SA
TRGNF
$0.70
-$0.89-55.98%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -98.50% | -71.66% | -38.66% | -28.81% | -24.54% |
| Total Other Revenue | -5.86% | -20.77% | -33.42% | -18.91% | -4.77% |
| Total Revenue | -19.54% | -22.86% | -25.79% | -22.78% | -22.19% |
| Cost of Revenue | 15.90% | 7.35% | -1.21% | -2.39% | -5.84% |
| Gross Profit | -28.81% | -19.12% | -9.00% | -6.70% | -1.95% |
| SG&A Expenses | 11.09% | 14.87% | 19.00% | 5.31% | -9.39% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -102.30% | -103.53% | -104.77% | -18.44% | 777.70% |
| Total Operating Expenses | 10.85% | 4.72% | -1.38% | -1.26% | -3.51% |
| Operating Income | -18.85% | -12.45% | -5.87% | -5.68% | -3.00% |
| Income Before Tax | -52.26% | -4.25% | 29.14% | 28.70% | 30.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.26% | -4.25% | 29.14% | 28.70% | 30.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.26% | -4.25% | 29.14% | 28.70% | 30.03% |
| EBIT | -18.85% | -12.45% | -5.87% | -5.68% | -3.00% |
| EBITDA | -20.91% | -14.47% | -7.86% | -6.91% | -3.44% |
| EPS Basic | -32.74% | 4.29% | 29.87% | 29.35% | 30.55% |
| Normalized Basic EPS | -32.96% | 23.25% | 50.55% | 50.34% | 51.12% |
| EPS Diluted | -32.96% | 5.11% | 31.04% | 30.34% | 31.33% |
| Normalized Diluted EPS | -32.96% | 23.25% | 50.55% | 50.34% | 51.12% |
| Average Basic Shares Outstanding | 15.98% | 8.60% | 1.17% | 1.13% | 1.09% |
| Average Diluted Shares Outstanding | 15.98% | 8.60% | 1.17% | 1.13% | 1.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |